China’s Evolving Innovation Landscape: New DIA Global Forum Article
A new article authored by CIRS' Dr Tina Wang and Dr Neil McAuslane, together with Prof Jin Wang of the OmniChain Med Institute, has been published in the September [...]
Evaluation of the UMBRA benefit-risk framework by ZAMRA – Chisha et al 2026
Transparent and consistent benefit-risk assessment is fundamental to regulatory decision making and stakeholder confidence in medicines regulation. This study evaluated the application of the Universal Methodology for Benefit-Risk Assessment (UMBRA) [...]
Assessing the implementation of regulatory reliance in Latin America
How effectively are regulatory authorities in Latin America implementing regulatory reliance in practice? This report presents findings from the first phase of a CIRS research project, showing that reliance [...]
Patient Involvement in the Asia Pacific – 2026 Workshop Report
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes in the Asia-Pacific.
Good Review Practices at the Zambian Medicines Regulatory Authority
Good Review Practices (GRevPs) are an important component of regulatory systems strengthening and support progress in World Health Organization (WHO) Global Benchmarking Tool (GBT) assessment. This poster was presented [...]
From vision to reality: Two decades of progress in global drug development and regulatory innovation
Twenty years ago, participants at a CIRS workshop explored ideas that at the time appeared ambitious, including rolling reviews, facilitated regulatory pathways, collaborative assessments and real-time data sharing. Many [...]
African Medicines Agency (AMA): Origins, Evolution and Future Prospects
This poster was presented at DIA 2026 and examines the development of the African Medicines Agency (AMA), tracing its evolution from the African Medicines Regulatory Harmonisation (AMRH) Programme to its [...]
CIRS 2025 Annual Report
The CIRS 2025 Annual Report highlights a year of independent research, global stakeholder engagement and evidence-based insights aimed at advancing regulatory and health technology assessment (HTA) policies and processes. Inside [...]
CIRS R&D Briefing 105 – HTA Landscape under the EU HTA Regulation
Baseline mapping of national HTA authorities across the EU and EEA The EU Health Technology Assessment Regulation (HTAR) has moved from policy to practice, with Joint Clinical Assessments (JCAs) [...]
Comparative review of 10 HTA systems – Dai 2026
Overview Health technology assessment (HTA) plays a key role in supporting evidence-informed healthcare decision making, pricing, reimbursement, and coverage decisions worldwide. As countries seek to strengthen health policy and [...]